The Heart-Brain Connection: What the Longevity Science Actually Says

Two patients asked me versions of the same question last month.

The first was in his forties, healthy, the kind of person who arrives with a spreadsheet. He wanted to know which biomarkers to track and which supplements to take to protect his brain for the next fifty years.

The second was in her sixties. Her mother had just been diagnosed with Alzheimer's disease, and she wanted to know what that meant for her own risk, and whether anything she did now would matter.

Different life stages, opposite emotional registers, same underlying question: what is the relationship between the health of my heart and the health of my brain, and what can I do about it?

This is one of the most active areas in medicine right now. It is also one of the most oversold. The honest answer separates into three parts: what is solid, what is oversold, and what is worth your time.

What is solid

For decades we treated cardiovascular disease and dementia as separate problems handled by separate specialists. That division is breaking down, and for good reason.

In 2024, the Lancet Commission on dementia prevention published its standing report and did something notable. It added high LDL cholesterol in midlife to its list of modifiable dementia risk factors. The Commission now estimates that roughly 45 percent of dementia cases worldwide are potentially preventable by addressing 14 risk factors across the lifespan, with about 7 percent tied specifically to elevated LDL from around age 40.

What makes this more than the usual observational hand-waving is the type of evidence behind it. The LDL conclusion draws on cohort data from more than a million people plus a Mendelian randomization analysis, a genetic method that helps separate correlation from causation. Each 1 mmol/L increase in LDL in people under 65 tracked with roughly an 8 percent higher incidence of all-cause dementia.

Put LDL alongside the other factors on that list, hypertension, diabetes, smoking, obesity, physical inactivity, and a clear message emerges. The vascular system that feeds your heart also feeds your brain. Protecting one tends to protect the other. The old clinical adage, that what is good for the heart is good for the brain, now has real data underneath it.

If you are the person worried about a parent's diagnosis, this is the encouraging part. Genetic risk is not destiny. The Commission's estimate holds even for people at elevated genetic risk, and most of the leverage sits in midlife, decades before symptoms appear.

What is oversold

Here is where I part ways with much of what you will hear on podcasts and read in optimization forums.

The gap between "this biomarker predicts risk" and "changing this biomarker reduces risk" is enormous. It is where most longevity advice quietly falls apart.

Consider omega-3 fatty acids, specifically DHA. The observational data are impressive. In the Framingham Heart Study, people in the top quartile of plasma DHA had a 47 percent lower risk of developing all-cause dementia. A later analysis in the children of that original cohort found a similar 49 percent lower risk of Alzheimer's disease in those with the highest red blood cell DHA. If you stopped reading there, you would buy fish oil today.

But when researchers ran the actual experiment, giving people omega-3 supplements and following their cognition over time, the benefit largely evaporated. A Cochrane review, the most rigorous form of evidence synthesis we have, found no benefit of omega-3 supplementation on cognitive function in older adults, and noted that direct evidence on preventing dementia is lacking. More soberingly, a 2026 analysis of participants in a major Alzheimer's study found that those taking omega-3 supplements actually declined somewhat faster on standard cognitive tests, a difference the authors linked to reduced brain glucose metabolism rather than to classic Alzheimer's changes. That finding is a single observational analysis and should not be over-read, but it is a useful splash of cold water.

This pattern, where a biomarker moves in the right direction but the health outcome does not follow, is one of the oldest lessons in medicine. It is why we run trials instead of trusting mechanisms. A high DHA level may simply be a marker of people who eat fish, exercise, and live in ways that protect the brain, rather than the cause of the protection. The supplement captures the molecule but not the life around it.

Cholesterol lowering carries its own version of this caution. LDL is a real risk factor, but the trials have not cleanly shown that lowering it prevents dementia. Observational studies suggest statin users get less dementia. Randomized trials have not confirmed it. Some of that apparent benefit is likely confounding. And the cholesterol circulating in your bloodstream does not cross into the brain, which manufactures its own, so the mechanism is vascular rather than direct. One large 2025 study even suggested a sweet spot rather than a lower-is-always-better relationship for the brain.

None of this means ignore your LDL. Treat it, in midlife, for your heart, and accept the probable brain benefit as a bonus rather than a guarantee. It means be skeptical of anyone selling you a single number to chase to zero.

What is worth your time

So where does that leave my two patients, and where does it leave you?

The interventions with the strongest evidence for protecting your brain are the same ones that protect your heart, and they are unglamorous. Manage blood pressure and blood sugar starting in midlife, not at 70. Do not smoke. Stay physically active. Treat elevated LDL when it is genuinely elevated. Protect your hearing and vision, both of which the Lancet Commission flags. Eat in a way that includes fish rather than a way that includes fish oil capsules. Sleep. Stay socially connected.

I know how this sounds. Boring. The fundamentals always are. But the effect sizes here are large and the evidence is deep, which is more than can be said for most of what gets marketed as brain optimization.

Where advanced testing and detailed workups earn their place is not in generating a longer supplement list. It is in precision. Knowing your APOE genotype can change how aggressively we monitor and intervene, and how we counsel your family. Detailed lipid particle testing can matter for someone with a confusing cardiovascular history. The value is in interpretation, in a physician who can tell you which of your numbers deserves your attention and which is noise dressed up as insight.

Why this is a concierge conversation

This is the kind of topic that does not fit into a 15-minute visit.

Sorting solid evidence from oversold evidence takes time. It takes a physician who has read the primary literature rather than the press release, who can hold two ideas at once: that the heart-brain connection is real, and that most of what is sold to exploit it is not. It takes knowing you well enough to tailor the answer, because the right approach for a 45-year-old optimizer is different from the right approach for someone watching a parent decline and wondering about herself.

That is the work I find most rewarding. Not handing patients a protocol, but helping them think clearly about complex, emotionally charged science, and then building something sustainable around the fundamentals that actually move the needle.

Both of my patients left with a plan. Neither plan involved a cabinet full of supplements. Both involved the basics, done consistently, with monitoring matched to their actual risk. That is usually where the evidence points, once you clear away the noise.

Paul Abramson, MD is the founder of My Doctor Medical Group, a concierge medical practice in San Francisco. He trained as an engineer at Stanford before completing medical school and residency at Stanford and UCSF, a combination that shapes his approach to medicine: rigorous about evidence, skeptical of complexity for its own sake, and focused on what actually works.

This content is for educational purposes only and does not constitute medical advice. Consult your physician before making changes to your health regimen.

Sources

• Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 2024.
• Schaefer EJ, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol, 2006.
• Sala-Vila A, et al. Red blood cell DHA and risk of incident Alzheimer's disease and all-cause dementia: Framingham Offspring Study. Nutrients, 2022.
• Cochrane review: Omega-3 fatty acids for the prevention of cognitive decline and dementia.
• Liao ZB, Hu ZC, Zeng GH, et al. The association between omega-3 supplementation and cognitive decline in older adults. The Journal of Prevention of Alzheimer's Disease, 2026;13(6):100569. DOI: 10.1016/j.tjpad.2026.100569.
• Lee M, Lee KJ, Kim J, et al. Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models. Journal of Neurology, Neurosurgery & Psychiatry, 2025;96(10):981-989. DOI: 10.1136/jnnp-2024-334708.
• American Heart Association Scientific Statement: Aggressive LDL-C lowering and the brain.